Prevalence, clinical features, and survival outcome trends of 627 patients with primary cutaneous lymphoma over 29 years: a retrospective review from single tertiary center in Korea-Reference-Cited by-同舟云学术

Prevalence, clinical features, and survival outcome trends of 627 patients with primary cutaneous lymphoma over 29 years: a retrospective review from single tertiary center in Korea

Published:2024-08-29 Issue:1 Volume:14 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Moon Ik Jun,Won Chong Hyun,Chang Sung Eun,Park Chan-Sik,Yoon Dok-Hyun,Song Si Yeol,Lee Mi Woo,Lee Woo Jin

Funder

Asan Institute for Life Sciences, Asan Medical Center

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41598-024-71210-y.pdf

Reference23 articles.

1. Willemze, R. et al. WHO-EORTC classification for cutaneous lymphomas. Blood 105, 3768–3785. https://doi.org/10.1182/blood-2004-09-3502 (2005).

2. Lee, W. J. et al. Relative frequency, clinical features, and survival outcomes of 395 patients with cutaneous lymphoma in Korea: A subgroup analysis per 10-year period. Acta Derm Venereol. 96, 888–893. https://doi.org/10.2340/00015555-2404 (2016).

3. Alaggio, R. et al. The 5th edition of the world health organization classification of haematolymphoid tumours: Lymphoid Neoplasms. Leukemia 36, 1720–1748. https://doi.org/10.1038/s41375-022-01620-2 (2022).

4. Olsen, E. et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European organization of research and treatment of cancer (EORTC). Blood 110, 1713–1722. https://doi.org/10.1182/blood-2007-03-055749 (2007).

5. Kim, Y. H. et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European organization of research and treatment of cancer (EORTC). Blood 110, 479–484. https://doi.org/10.1182/blood-2006-10-054601 (2007).